Get to know our clinical trials

Study of OMTX705 in combination with regorafenib and tislelizumab in patients with advanced or metastatic colorectal cancer

THE OBJECTIVE OF THIS TRIAL IS TO TEST WHETHER A NEW DRUG, OMTX705, IS SAFE AND WELL TOLERATED WHEN USED IN CONJUNCTION WITH TWO OTHER EXISTING DRUGS: REGORAFENIB (STIVARGA®) AND TISLELIZUMAB (TEVIMBRA®), AND TO DETERMINE THE MOST APPROPRIATE DOSE OF THESE DRUGS FOR USE IN FUTURE TRIALS AND FURTHER CLINICAL DEVELOPMENT OF OMTX705.

Imagen de la Dra. Ana Chopitea Ortega, especialista en Oncología Médica de la Clínica Universidad de Navarra. La Dra. Chopitea se dedica preferencialmente al tratamiento de los tumores gastrointestinales.
Dr. Ana Chopitea Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Gastrointestinal Cancer Area
Status
In recruitment
headquarters
Pamplona
Early phase

Technical Summary

  • PHASE 1B/2 DOSE ESCALATION STUDY OF OMTX705, A DRUG-CONJUGATED ANTIBODY AGAINST FIBROBLAST ACTIVATION PROTEIN, IN COMBINATION WITH REGORAFENIB AND TISLELIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER.
  • Code EudraCT: 2025-520743-33
  • Protocol number: OMTX705-004
  • Promoter: Oncomatryx Biopharm S.L.
  • Molecule/Drug: OMTX705

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION